Cargando…
Dabrafenib- and trametinib-associated glomerular toxicity: A case report
RATIONALE: Combined treatment with dabrafenib, a B-RAF inhibitor, and trametinib, a mitogen-activated protein kinase inhibitor, is an effective option for patients with metastatic melanoma. A few cases of acute kidney injury associated with tubulointerstitial nephritis and 1 case of nephrotic syndro...
Autores principales: | Jo, Eunmi, Rhee, Harin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735797/ https://www.ncbi.nlm.nih.gov/pubmed/35029901 http://dx.doi.org/10.1097/MD.0000000000028485 |
Ejemplares similares
-
Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021) -
Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017) -
Factors Associated With Pathogenicity of Anti-Glomerular Basal Membrane Antibodies: A Case Report
por: Ossman, Rime, et al.
Publicado: (2016) -
Pembrolizumab-induced focal segmental glomerulosclerosis: A case report
por: Kim, Da Woon, et al.
Publicado: (2021) -
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)